-
Mashup Score: 377
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr…
Source: www.nejm.orgCategories: General Medicine NewsTweet
-
Mashup Score: 37
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease. However, their effect on hyperkalemia has not been systematically evaluated. Methods: A meta-analysis was conducted using individual participant data from randomized, double-blind, placebo-controlled clinical outcome trials with SGLT2 inhibitors in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease in whom serum potassium levels were routinely measured. The primary outcome was time to serious hyperkalemia, defined as central laboratory–determined serum potassium ≥6.0 mmol/L, with other outcomes i
Source: www.ahajournals.orgCategories: General Medicine NewsTweet-
#CONFIDENCE Safer Together 🤝🏾 Starting upfront combination of #SGLT2i empagliflozin & #nsMRA finerenone leads to lower risks of clinically relevant hyperkalemia than starting finerenone alone. Magnitude of protection (~15-20%) well aligned w prior data https://t.co/HvZMKsH9gK https://t.co/l2xBytBkPM https://t.co/ziVvrqG4f7
-
-
Mashup Score: 374
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 https://t.co/UClYe6WBrn https://t.co/mI3Gh7f5iQ
-
-
Mashup Score: 374
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 https://t.co/UClYe6WBrn https://t.co/mI3Gh7f5iQ
-
-
Mashup Score: 374
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 https://t.co/UClYe6WBrn https://t.co/mI3Gh7f5iQ
-
-
Mashup Score: 81
Effects of digitoxin compared to placebo on efficacy and safety in patients with heart failure and reduced ejection fraction (HFrEF). Primary endpoint: time to all-cause death and first hospitalizati…
Source: onlinelibrary.wiley.comCategories: General Medicine NewsTweet-
Back to the Future at #HeartFailure2025 Revisiting the contemporary role of digoxin in #HFrEF Guidelines have serially downgraded its recommendation & use globally has declined Will #DIGITHF (n=1212 pts) be sufficiently powered to change practice? https://t.co/YBXB7qUXHC https://t.co/TCdOk1NrQV
-
-
Mashup Score: 45Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant | Circulation: Heart Failure - 1 month(s) ago
Request permissions for this article. Division of Cardiology, Medical University of South Carolina and Ralph H. Johnson Veteran Affairs Medical Center, Charleston, SC Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital,
Source: www.ahajournals.orgCategories: General Medicine NewsTweet-
Simultaneous Publication with #HeartFailure2025 in @CircHF Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant Suggests large subclinical risk & close monitoring for disease progression among carriers #MedIQHF2025 https://t.co/UiuSS7fg0o
-
-
Mashup Score: 23Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B - 1 month(s) ago
AbstractBackgroundPatients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have high mortality and morbidity. Vutrisiran, a subcutaneous RNA interference therapeutic, reduced the compo…
Source: www.jacc.orgCategories: General Medicine NewsTweet-
#HeartFailure2025 Simultaneous Publication in @JACCJournals Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B https://t.co/JuZg0VI7gy #MedIQHF2025 https://t.co/rmyjNbKNdN
-
-
Mashup Score: 20Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Pilot Randomized Controlled Trial | Circulation - 1 month(s) ago
View all available purchase options and get full access to this article. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S-Y, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–2463. doi: 10.1093/eurheartj/eht187 Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller
Source: www.ahajournals.orgCategories: General Medicine NewsTweet-
Some new randomized head to head data, although small sample sizes https://t.co/4AIwpqq2G0 Observational/RWE comparisons among users of either drug are also emerging #SPIRITHF (PBO-controlled) is expected this year and will be a second shot on goal for spironolactone in #HFpEF https://t.co/vkQCtpX5MH
-
-
Mashup Score: 20Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Pilot Randomized Controlled Trial | Circulation - 1 month(s) ago
View all available purchase options and get full access to this article. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S-Y, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–2463. doi: 10.1093/eurheartj/eht187 Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller
Source: www.ahajournals.orgCategories: General Medicine NewsTweet-
Some new randomized head to head data, although small sample sizes https://t.co/4AIwpqq2G0 Observational/RWE comparisons among users of either drug are also emerging #SPIRITHF (PBO-controlled) is expected this year and will be a second shot on goal for spironolactone in #HFpEF https://t.co/vkQCtpX5MH
-
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 https://t.co/UClYe6WBrn https://t.co/mI3Gh7f5iQ